English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objectives   HIV  treatment guidelines endorse switching or simplification of antiretroviral therapy in therapy‐experienced patients with suppressed viraemia; ritonavir discontinuation may also enhance tolerability and reduce long‐term adverse events ( AEs ). This open‐label, multicentre, noninferiority study enrolled  HIV ‐1‐infected, treatment‐experienced adults with confirmed  HIV ‐1  RNA  ≤ 75  HIV ‐1  RNA  copies/mL currently receiving tenofovir/emtricitabine + atazanavir/ritonavir ( TDF / FTC  +  ATV /r) for ≥ 6 months with no reported history of virological failure.    Methods  Participants were randomized 1:2 to continue current treatment or switch to abacavir/lamivudine + atazanavir ( ABC /3TC +  ATV ). Endpoints included the proportion of participants with  HIV ‐1  RNA  < 50 copies/mL by time to loss of virological response ( TLOVR ),  AEs , fasting lipids, and inflammatory, coagulation, bone and renal biomarkers.    Results  After 48 weeks, 76% (152 of 199) of  ABC /3TC +  ATV ‐treated and 79% (77 of 97) of  TDF / FTC  +  ATV /r‐treated participants had  HIV ‐1  RNA  < 50 copies/mL ( TLOVR ;  P  = 0.564). Other efficacy analyses yielded similar results. Rates of new grade 2–4  AEs  were 45% in both groups, but an excess of hyperbilirubinaemia made the rate of treatment‐emergent grade 3–4 laboratory abnormalities higher with  TDF / FTC  +  ATV /r (36%) compared with  ABC /3TC +  ATV  (19%). Most fasting lipid levels remained stable over time; high‐density lipoprotein ( HDL ) cholesterol increased modestly in  ABC /3TC +  ATV ‐treated participants. Bone and renal biomarkers improved significantly between baseline and week 48 in participants taking  ABC /3TC +  ATV  and were stable in participants taking  TDF / FTC  +  ATV /r. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups.Conclusions  The  ABC /3TC +  ATV  treatment‐switch group had similar viral suppression rates up to 48 weeks to the  TDF / FTC  +  ATV /r comparator group, with lower rates of moderate‐ to high‐grade hyperbilirubinaemia and improvements in bone and renal biomarkers.

hiv medicine

The  ASSURE  study:  HIV ‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir